AKBA Akebia Therapeutics Inc.

-0.24  -4%
Previous Close 6.02
Open 6.04
Price To Book 4.74
Market Cap 675609854
Shares 116,887,518
Volume 646,325
Short Ratio
Av. Daily Volume 1,141,417

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019, with top-line results expected in 2020.
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 2 trial data due 1H 2019.
Vadadustat - FO2RWARD
Renal anemia
Approved Sept 5, 2014.
Phase 3 data due 1Q 2020.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 data due mid-2020.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
sNDA FDA Approval announced November 7, 2017.
Iron deficiency anemia in non-dialysis dependent CKD patients

Latest News

  1. What Did Akebia Therapeutics, Inc.’s (NASDAQ:AKBA) CEO Take Home Last Year?
  2. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  3. Akebia Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
  4. Hedge Funds Are Crazy About Akebia Therapeutics Inc (AKBA)
  5. Seth Klarman Gains Stake in Akebia Therapeutics
  6. Abrams Capital Management’s Return, AUM and Holdings
  7. Akebia Poised To Become 'Renal Powerhouse' With Keryx Merger, Raymond James Says
  8. Why Akebia Therapeutics Is Soaring Today
  9. Akebia Therapeutics and Keryx Biopharmaceuticals Complete Merger, Creating Fully Integrated Renal Company
  10. Akebia Therapeutics Shareholders Approve Merger with Keryx
  11. Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
  12. ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
  13. Leading Independent Proxy Advisory Firm ISS Recommends Akebia Shareholders Vote “FOR” Proposed Merger with Keryx
  14. What Kind Of Shareholders Own Akebia Therapeutics Inc (NASDAQ:AKBA)?
  15. Akebia Therapeutics to Participate in Upcoming Investor Conferences
  16. The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal
  17. Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company